609 Stock Overview
A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
ABIONYX Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.13 |
| 52 Week High | €1.41 |
| 52 Week Low | €0.85 |
| Beta | -0.13 |
| 1 Month Change | 17.38% |
| 3 Month Change | -3.59% |
| 1 Year Change | -4.89% |
| 3 Year Change | -9.76% |
| 5 Year Change | 189.23% |
| Change since IPO | -90.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 609 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.4% | -3.5% | -0.4% |
| 1Y | -4.9% | -36.9% | 8.6% |
Return vs Industry: 609 exceeded the German Biotechs industry which returned -36.9% over the past year.
Return vs Market: 609 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 609 volatility | |
|---|---|
| 609 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 609 has not had significant price volatility in the past 3 months.
Volatility Over Time: 609's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 63 | Cyrille Tupin | abionyx.com |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
ABIONYX Pharma SA Fundamentals Summary
| 609 fundamental statistics | |
|---|---|
| Market cap | €39.16m |
| Earnings (TTM) | -€3.50m |
| Revenue (TTM) | €4.60m |
8.5x
P/S Ratio-11.2x
P/E RatioIs 609 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 609 income statement (TTM) | |
|---|---|
| Revenue | €4.60m |
| Cost of Revenue | €4.00m |
| Gross Profit | €600.00k |
| Other Expenses | €4.10m |
| Earnings | -€3.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 13.04% |
| Net Profit Margin | -76.09% |
| Debt/Equity Ratio | 89.8% |
How did 609 perform over the long term?
See historical performance and comparison